Study Title
A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Study Details
Description:
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Sponsor:
AstraZenecaContacts:
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
1-877-240-9479
Government Study Link:
NCT06879041 - Click here to see study onClinicalTrials.gov
Drug Details
[225Ac]-AZD2284
Isotope(s):
- ACTINIUM-225
ACTINIUM-225
Radioisotope: Ac-225
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 9.9 Days
Decay Mode: ALPHA, GAMMA
Energy: 5.8-8.4 MeV
Range: 47-85 micrometers
Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
Status: Clinical Trials Only
Target(s):
- STEAP2
Ligand: Antibodies
